BIOTHERAPIES FOR LIFE

Serial Number 88708639
606

Registration Progress

Application Filed
Nov 27, 2019
Under Examination
Oct 6, 2020
Approved for Publication
Aug 11, 2020
Published for Opposition
Aug 11, 2020
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: BIOTHERAPIES FOR LIFE
Previous Owner: CSL BEHRING L.L.C.
Classes: 005

Trademark Image

BIOTHERAPIES FOR LIFE

Basic Information

Serial Number
88708639
Filing Date
November 27, 2019
Published for Opposition
August 11, 2020
Abandonment Date
November 6, 2023
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Nov 6, 2023
Classes
005

Rights Holder

CSL BEHRING L.L.C.

16
Address
1020 First Avenue
King of Prussia, PA 19406

Ownership History

CSL BEHRING L.L.C.

Original Applicant
16
King of Prussia, PA

CSL BEHRING L.L.C.

Owner at Publication
16
King of Prussia, PA

Legal Representation

Attorney
Scott D. Woldow

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

44 events
Date Code Type Description Documents
Nov 6, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Nov 6, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Mar 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 8, 2023 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 6, 2023 EXT5 S SOU EXTENSION 5 FILED Loading...
Mar 6, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 8, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 6, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Sep 6, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Sep 6, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 9, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 7, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
Mar 7, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Mar 7, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 7, 2021 NOAC E CORRECTED NOA E-MAILED Loading...
Oct 6, 2021 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Sep 28, 2021 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Sep 28, 2021 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Sep 13, 2021 INOA I AMENDMENT AFTER NOA NOT ENTERED Loading...
Sep 21, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 13, 2021 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED Loading...
Sep 9, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 7, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 7, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 7, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 10, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 8, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 8, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 8, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 6, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 11, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 11, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 22, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 9, 2020 ALIE A ASSIGNED TO LIE Loading...
Jul 4, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 3, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 2, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 2, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 24, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 24, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 24, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 17, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 4, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 30, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations and substances for the prevention and treatment of blood or bleeding disorders, and autoimmune disorders; pharmaceutical preparations and substances to support the function of the human immune system; blood products, namely, human albumin, blood clotting factors and immunoglobulins for medical and clinical use; products derived from recombinant DNA technology, namely, blood clotting factors; antihemophilic factor; Pharmaceutical preparations for the treatment of blood diseases, illnesses and conditions; vaccines

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOTHERAPIES"